Most pain medications target one pathway. Opioids block opioid receptors. NSAIDs inhibit COX enzymes. Acetaminophen… nobody is entirely sure, honestly. Cannabinoids work differently: they hit multiple receptor systems simultaneously, including CB1 and CB2 receptors distributed throughout the central and peripheral nervous system, as well as TRP channels, PPAR receptors, and opioid receptors. That multi-pathway profile is part of why research keeps finding cannabinoid effects across pain types that respond differently to single-mechanism drugs.
🧪 Lab Tested | 👩💼 Woman-Owned | 🏆 Est. 2017
How Cannabinoids Address Pain
Pain perception involves at least three stages: signal generation at the site of injury or inflammation, transmission through peripheral nerves to the spinal cord, and processing in the brain. Cannabinoids can intervene at all three.
At the injury site, CB2 receptors on immune cells regulate inflammatory cytokine release. When activated, they reduce the volume of pro-inflammatory signaling that generates and sustains peripheral pain. This is the mechanism most relevant to topical cannabinoid products: the cannabinoid doesn’t need to reach the bloodstream to activate CB2 receptors in tissue directly beneath the skin.
In peripheral nerves, CB1 receptors modulate how strongly pain signals are transmitted. TRPV1 channels (which respond to heat, acid, and capsaicin) are also regulated by endocannabinoids, which is why cannabinoids can affect burning and thermal pain that has a different character from mechanical pain. In the spinal cord, cannabinoids reduce the intensity of incoming pain signals before they reach the brain. And centrally, THC in particular modulates the emotional response to pain, which may be why some users report that pain still exists but no longer commands their full attention in the same way.
The endocannabinoid system is also directly coupled to the opioid system through shared signaling pathways. Cannabinoids can potentiate opioid analgesia, which is clinically relevant for anyone who uses both: the same pain relief may be achievable at a lower opioid dose when cannabinoids are co-administered. This is a conversation to have with a prescriber, not a self-experiment.
Which Pain Types Respond Best
Neuropathic pain
Nerve damage pain (neuropathy, sciatica, fibromyalgia) has the strongest clinical evidence for cannabinoid effectiveness. THC’s effect on central pain processing and CB1-mediated nerve signal modulation are well-matched to the burning, shooting quality of neuropathic pain that NSAIDs address poorly.
Inflammatory / arthritic pain
CB2 receptor activation reduces inflammatory cytokine production in joint and connective tissue. Topical cannabinoids applied directly to affected joints deliver this effect locally without systemic exposure. Multiple controlled animal studies and substantial human observational data support this mechanism.
Musculoskeletal pain
Muscle tension, back pain, and post-exercise soreness respond to both the peripheral CB1/CB2 mechanisms and the central muscle-relaxant properties of cannabinoids, particularly THC. The topical route is most appropriate for localized muscle pain; ingested or inhaled formats better address systemic or diffuse muscular involvement.
Chronic pain with sleep disruption
Pain disrupts sleep; poor sleep lowers the pain threshold. Cannabinoids address both ends of the cycle simultaneously: analgesic effects reduce pain load, and sedating cannabinoids (CBN, THC at appropriate doses) improve sleep quality. The bidirectional benefit is more than additive.
Acute post-surgical or traumatic pain is a different category and should be managed with appropriate medical care.
What the Research Shows
Neuropathic pain
A 2018 Cochrane systematic review by Mücke et al. analyzed 16 randomized controlled trials on cannabinoids for chronic neuropathic pain (PMID 29513392). Results: cannabinoid users were more likely to achieve 30% pain reduction (number needed to treat: 11) compared to placebo. Significant improvements in sleep and emotional function were also documented. The authors noted the evidence base is limited by short trial durations, but the effect was consistent across study designs.
Topical CBD
Hammell et al. 2016 (PMID 26517407) demonstrated transdermal CBD reduced joint inflammation and pain-related behaviors in an arthritic rat model; this established the mechanism for topical cannabinoid effectiveness in joint pain without systemic psychoactive effects. Human clinical trials specifically on topical CBD for arthritis are ongoing but limited; the mechanism study is solid.
Broad pain outcomes
Aviram & Samuelly-Leichtag 2017 (PMID 28934780) reviewed cannabis-based medicines across multiple pain conditions. Significant improvements in chronic pain intensity, quality of life, and sleep quality were documented across the studies reviewed.
Honest limitations
Most cannabinoid pain trials are short (weeks, not months), underpowered, and rely on variable cannabinoid products that resist direct comparison. The majority of the strongest evidence involves smoked or vaporized cannabis rather than oral or topical formulations. Regulatory restrictions on research have created a gap between what the clinical data can confirm and what decades of human use suggests. The evidence is promising but not settled at the level of established analgesics.
Delivery Methods: Topical vs Ingested vs Inhaled
The delivery method determines what kind of pain can be addressed, where, and how quickly. Getting this match right matters more than which specific product you choose.
| Method | Onset | Duration | Best for | Drug test risk |
| Topical cream | 10–30 min | 3–6 hr | Localized joint, muscle, nerve pain | Very low (D8 topical); does not typically reach systemic levels |
| Sublingual tincture | 15–45 min | 4–6 hr | Diffuse or systemic pain, chronic management | Low but real (full-spectrum trace D9). D8 tincture: will produce a positive drug test |
| Gummies / edibles | 45–90 min | 6–8 hr | Longer-duration coverage, pain-disrupted sleep | D9 products: will produce a positive drug test. THC-free CBD gummies: very low risk |
| Vape / inhaled | 2–5 min | 1–3 hr | Acute pain flares, rapid onset needed | D8, D9, THCa products: will produce a positive drug test |
Topicals for localized pain
Topicals are the most targeted delivery method. Cannabinoids applied to skin penetrate to the dermis, muscle, and joint tissue beneath and activate CB1 and CB2 receptors locally without entering systemic circulation in meaningful amounts. No high. No drug test concern for Delta-8 topicals (the cannabinoid doesn’t reach blood in detectable concentrations from topical application). No systemic side effects. “Pain is gone in minutes,” KRISTINE B. (Delta-8 THC Pain Relief Cream). “I have lower back pain due to arthritis and have tried many different products for relief with minimal relief. Delta 8 cream really works! Immediate relief!” Philip H.
The limitation of topicals is geographic: they work where you put them, and that’s it. For diffuse pain, multiple application sites, or pain that’s primarily central in character (fibromyalgia, widespread musculoskeletal involvement), systemic delivery is more appropriate.
Tinctures for systemic coverage
Sublingual tinctures absorb through the mucous membranes under the tongue and reach the bloodstream in 15 to 45 minutes. This makes them the fastest systemic delivery method after inhalation. They’re well-suited to chronic, diffuse, or recurrent pain that doesn’t have a single anatomical address. “This CBD Tincture helps me get through my day nearly pain free!” Nancy B. The Delta-8 THC Tincture adds CB1 agonism alongside CBD’s CB2 and indirect pathways, which provides stronger analgesic coverage for neuropathic or severe chronic pain.
One important note: the Delta-8 Tincture is psychoactive and will produce a positive result on a standard drug test. For anyone subject to drug testing, the CBD Tincture (full-spectrum, with CBG boost) is the appropriate systemic option, though it still carries low but real drug test risk from trace Delta-9 THC in a full-spectrum formulation.
Gummies for sustained coverage
The slow onset of gummies (45 to 90 minutes) is offset by longer duration (6 to 8 hours), which makes them particularly useful for pain that persists through the night or through a full workday. “One of these gummies taken at bedtime has helped greatly at getting a full night sleep. Also mellow and helps with my back pain,” Duane F. For people whose pain disrupts sleep, the simultaneous sleep and analgesic effects of Delta-8 or THC/CBN gummies represent a meaningful quality-of-life improvement.
Dosing Guidance
Start at the lowest effective dose and adjust upward slowly. Higher doses aren’t linearly more effective and can introduce sedation, next-day effects, or (with THC) paradoxical anxiety. The therapeutic window varies significantly by individual, tolerance level, and type of pain.
Topical dosing
Apply a pea- to dime-sized amount to the affected area and rub in until fully absorbed. Reapply every 3 to 6 hours as needed. Consistent daily application produces better cumulative results than as-needed use for chronic conditions. “When you apply the cream on a schedule it works better than putting it on when you remember. The pain in my knees goes from a 6 to a 3–4,” Sheryl C. No upper limit applies to topicals the way it does to ingested cannabinoids, but applying more than can be absorbed doesn’t help.
Tincture dosing
For the TribeTokes Delta-8 THC Tincture and CBD Tincture (both 1,800mg per 30mL at 60mg/mL): start at a quarter dropper (15mg) held under the tongue for 60 to 90 seconds, then swallowed. Evaluate over one week before adjusting. Most users find their effective analgesic range between 15 and 45mg per dose, taken once or twice daily. Psychoactive effects from the Delta-8 Tincture should be evaluated before operating machinery or taking on tasks requiring full concentration.
Gummy dosing
Start with half a gummy (or one low-dose gummy) and wait the full 90 minutes before deciding the dose was insufficient. The most common dosing error with edibles is redosing too early when onset is slow. For pain that peaks at night, take gummies 60 to 90 minutes before bed to coordinate peak effect with sleep onset.
TribeTokes Pain Products
Topical: Localized Pain
Delta-8 THC Pain Relief Cream
★★★★★ 4.69 from 335 reviews
1,000mg Delta-8 THC
Menthol + Camphor
Arnica + Aloe
Non-Psychoactive (topical)
1,000mg Delta-8 THC per jar, applied topically for local CB1/CB2 activation in skin, muscle, and joint tissue. Non-psychoactive in this format; topical cannabinoids do not typically reach systemic blood concentrations. Menthol and camphor provide counterirritant activity for immediate sensation; the cannabinoid layer sustains the effect for 3 to 6 hours. Available in travel size and multi-jar packs. “I have severe RA and a torn rotator cuff that can’t be operated on. I have tried everything for pain. This. Stuff. Works. I can rub it in and get a good 4–5 hours of relief,” Kathryn E.
Topical: THC-Free Option
CBD Pain Relief Cream
★★★★★ 4.69 from 35 reviews
1,000mg CBD
Essential Oil Blend
Arnica + Aloe
Non-Psychoactive
Same 1,000mg concentration as the Delta-8 cream, with CBD’s stronger CB2 and anti-inflammatory receptor profile. Lighter menthol sensation. Suited for inflammatory pain (arthritis, joint inflammation) or anyone who prefers no THC in their topical. “This cream works amazing. I hurt my shoulder and I apply a dime size amount and it relieves the pain even more so the next day,” Kelly W. Full-spectrum formulation carries trace Delta-9 THC; review COA at tribetokes.com/certificates-of-analysis.
Tincture: Systemic Coverage
Delta-8 THC Tincture
★★★★★ 4.89 from 28 reviews
Full CB1 agonism for systemic pain management. Onset 15 to 45 minutes sublingually; duration 4 to 6 hours. Well-suited for neuropathic pain, diffuse chronic pain, or pain that lacks a single anatomical location topicals can address. Delta-8 THC will produce a positive result on standard drug tests. Psychoactive; evaluate effect on cognition before taking for workplace pain management. “Provides great pain relief for my rheumatoid arthritis,” John G. COAs at tribetokes.com/certificates-of-analysis.
Frequently Asked Questions
Research suggests yes for certain pain types, particularly neuropathic and inflammatory pain. A 2018 Cochrane review of 16 randomized controlled trials found cannabinoid users were significantly more likely to achieve meaningful pain reduction than placebo groups. A 2017 review across multiple pain conditions found consistent improvements in chronic pain intensity, sleep quality, and quality of life. The evidence is strongest for neuropathic pain (nerve damage, burning, shooting pain) and weakest for acute traumatic pain. Most controlled trials used smoked or vaporized cannabis; the evidence base for oral and topical formulations is smaller but growing.
They work through different mechanisms and suit different pain profiles. THC activates CB1 receptors more directly and is more effective for neuropathic pain, central pain processing, and pain with a significant anxiety component. CBD has stronger CB2 activity, which is particularly relevant for inflammatory pain; it also lacks psychoactive effects and doesn’t suppress REM sleep. In practice, combination products (CBD+THC or CBD+Delta-8) tend to outperform either alone because they cover more receptor systems simultaneously. The route also matters: topicals favor CBD or Delta-8 for localized inflammatory pain; systemics favor whichever cannabinoid matches the dominant pain mechanism.
It depends on the product. Delta-8 THC Tincture and products containing Delta-9 THC will produce a positive result on standard drug tests with regular use. Delta-8 THC topical creams do not typically reach systemic blood concentrations that trigger a positive test, but TribeTokes cannot guarantee a negative result. CBD-only topicals carry very low risk from trace THC in full-spectrum formulations. Anyone subject to regular drug testing should review COAs at tribetokes.com/certificates-of-analysis and choose products accordingly.
Topical creams: 10 to 30 minutes for the menthol/camphor counterirritant effect; cannabinoid receptor activity continues building over 30 to 60 minutes. Sublingual tinctures: 15 to 45 minutes. Gummies: 45 to 90 minutes. The most common mistake is concluding a dose didn’t work before the full onset window has passed, then redosing and ending up with more than intended. For chronic pain management, consistent daily use over one to two weeks produces more reliable results than episodic dosing.
Topical cannabinoids carry the lowest interaction risk because they remain local. Ingested cannabinoids are metabolized by CYP450 liver enzymes, the same pathway as many pain medications including opioids, NSAIDs, and anticonvulsants. CBD specifically inhibits CYP3A4 and CYP2D6, which can raise blood levels of co-administered drugs. Discuss with your prescriber before adding cannabinoid products to an existing pain regimen, particularly if you’re on opioids, blood thinners, or anticonvulsants.
Topical cannabinoids activate CB1 and CB2 receptors in the skin, muscle, and joint tissue immediately beneath the application site. They do not cross into systemic circulation in meaningful amounts at standard doses, so they never reach the brain’s CB1 receptors where THC’s psychoactive effects occur. Topical Delta-8 THC cream is generally low-risk for drug testing for exactly this reason; ingested Delta-8 THC carries a high certainty of a positive result.
A pea- to dime-sized amount per application area is appropriate for most joints and muscle groups. Larger areas (back, thighs) may require more. Rub in thoroughly until fully absorbed; the absorption is the delivery mechanism, so partially absorbed cream sitting on the surface of skin isn’t providing the full effect. Apply every 3 to 6 hours for ongoing pain. More cream above the absorption threshold doesn’t increase effect; frequency is a more useful variable than dose volume for chronic conditions.
Delta-8 THC activates CB1 receptors with somewhat lower potency than Delta-9 THC. The analgesic and anti-inflammatory effects travel the same receptor system as Delta-9, but the psychoactive profile is milder. For many users, this makes it preferable for daytime pain management where full cognitive clarity matters. The pain relief evidence base for Delta-8 specifically is thinner than for Delta-9, but the receptor mechanism is well-established. Topical Delta-8 reaches CB1 and CB2 receptors locally without psychoactive effects; ingested or sublingual Delta-8 produces systemic effects and will produce a positive drug test result.
Topicals for Local. Tinctures for Systemic.
Three formats, three pain profiles. COA on every batch. Lab-tested for potency and purity.